An interim update on the phase I/II clinical trial conducted in Monza and Bergamo, Italy, reported promising clinical response, safety with only grade 1 and 2 cytokine release syndrome (CRS) and persistence of CD19-CAR-CIK cells (ASH, 16 December 2020). Here, CD19 is linked to congenital rubella syndrome.